BR0209251A - Vacina contra vìrus da febre aftosa - Google Patents

Vacina contra vìrus da febre aftosa

Info

Publication number
BR0209251A
BR0209251A BR0209251-4A BR0209251A BR0209251A BR 0209251 A BR0209251 A BR 0209251A BR 0209251 A BR0209251 A BR 0209251A BR 0209251 A BR0209251 A BR 0209251A
Authority
BR
Brazil
Prior art keywords
foot
mouth disease
vaccine
animals
disease virus
Prior art date
Application number
BR0209251-4A
Other languages
English (en)
Inventor
J. Grubman Marvin
Chinsangaram Jarasvech
Koster Marla
Moraes Mauro
Original Assignee
Us Agriculture
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Agriculture filed Critical Us Agriculture
Publication of BR0209251A publication Critical patent/BR0209251A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/135—Foot- and mouth-disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

"VACINA CONTRA VìRUS DA FEBRE AFTOSA". Uma proteção precoce em animais suscetíveis à febre aftosa pode ser alcançada pela inoculação dos animais com uma vacina compreendendo uma seq³ência de DNA de interferon. Um dia após a inoculação, os animais têm se mostrado protegidos contra a exposição ao vírus de febre aftosa virulento. A co-administração com uma vacina efetiva contra o vírus da febre aftosa proporciona uma proteção anterior ao desenvolvimento de imunidade específica, uma característica especialmente desejável em um surto de febre aftosa.
BR0209251-4A 2001-04-26 2002-04-26 Vacina contra vìrus da febre aftosa BR0209251A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28634501P 2001-04-26 2001-04-26
US10/128,463 US8058248B2 (en) 2001-04-26 2002-04-24 Foot and mouth disease virus vaccine comprising interferons
PCT/US2002/013247 WO2002087336A1 (en) 2001-04-26 2002-04-26 Foot and mouth disease virus vaccine

Publications (1)

Publication Number Publication Date
BR0209251A true BR0209251A (pt) 2005-02-09

Family

ID=26826603

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209251-4A BR0209251A (pt) 2001-04-26 2002-04-26 Vacina contra vìrus da febre aftosa

Country Status (13)

Country Link
US (1) US8058248B2 (pt)
EP (1) EP1389043B1 (pt)
JP (1) JP2004530677A (pt)
CN (1) CN100422322C (pt)
AR (1) AR040623A1 (pt)
AT (1) ATE437656T1 (pt)
AU (1) AU2002303503B2 (pt)
BR (1) BR0209251A (pt)
CA (1) CA2445266A1 (pt)
DE (1) DE60233127D1 (pt)
MX (1) MXPA03009763A (pt)
NZ (1) NZ529305A (pt)
WO (1) WO2002087336A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007059461A2 (en) * 2005-11-10 2007-05-24 Genvec, Inc. Adenoviral vector-based foot-and-mouth disease vaccine
CN100572541C (zh) * 2007-05-28 2009-12-23 中国农业科学院兰州兽医研究所 口蹄疫病毒双效疫苗载体、其制备方法及应用
WO2011091027A2 (en) * 2010-01-19 2011-07-28 The United States Of America, As Represented By The Secretary Of Agriculture Recombinant live attenuated foot-and-mouth disease (fmd) vaccine containing mutations in the l protein coding region
CN104774856B (zh) * 2011-04-25 2017-12-08 中国农业科学院兰州兽医研究所 对口蹄疫病毒有抑制作用的干扰靶序列
GB201111183D0 (en) * 2011-06-30 2011-08-17 Animal Health Inst Peptide
CN102988970B (zh) * 2011-09-19 2014-06-18 内蒙古必威安泰生物科技有限公司 口蹄疫纯化疫苗及其制备方法和应用
CN102363043B (zh) * 2011-10-09 2013-05-01 中国农业科学院兰州兽医研究所 一种猪用c型口蹄疫基因工程疫苗佐剂及其制备方法
KR101329348B1 (ko) * 2012-05-31 2013-11-15 대한민국 돼지 인터페론 알파-돼지 인터페론 감마를 동시 발현하는 재조합 아데노바이러스
CN103592441B (zh) * 2013-10-29 2015-06-17 王明丽 一种重组猪干扰素ɑ双抗体夹心法免疫胶体金检测试纸条的制备方法
CN106546747B (zh) * 2016-10-31 2019-03-01 江苏众红生物工程创药研究院有限公司 一种干扰素生物学活性的检测方法
CN108103034B (zh) * 2017-12-15 2022-06-24 云南农业大学动物医学院 同时表达A型、O型和Asia-1型口蹄疫病毒VP1基因重组腺病毒、构建方法及应用
CN110343164A (zh) * 2019-08-22 2019-10-18 安阳工学院 一种高活性7位点突变的猪干扰素α突变体及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831023A (en) 1982-11-01 1998-11-03 Genentech, Inc. Recombinant animal interferon polypeptides
US4795436A (en) 1983-11-14 1989-01-03 Bio-Mimetics, Inc. Bioadhesive composition and method of treatment therewith
US4732971A (en) * 1985-06-03 1988-03-22 Eli Lilly And Company Synthetic vaccines for foot and mouth disease
US5672510A (en) 1990-01-19 1997-09-30 Genetic Therapy, Inc. Retroviral vectors
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
CN1054544C (zh) * 1993-10-21 2000-07-19 复旦大学 家畜口蹄疫病毒多肽疫苗及其制备方法
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US6045802A (en) 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US6221361B1 (en) 1995-01-19 2001-04-24 Syntro Corporation Recombinant swinepox virus
US5612040A (en) * 1995-04-07 1997-03-18 The United States Of America As Represented By The Secretary Of Agriculture Non-infectious foot-and-mouth disease viruses
US5824316A (en) * 1996-05-24 1998-10-20 The United States Of America As Represented By The Secretary Of Agriculture Leader-proteinase deleted foot-and-mouth disease viruses and their use as vaccines
DE19638044A1 (de) * 1996-09-18 1998-03-19 Bayer Ag Immunogene Peptide von Maul- und Klauenseuchen-Viren
AU4808097A (en) * 1996-10-18 1998-05-15 Canji, Inc. Methods and compositions for delivery and expression of interferon-alpha nucleic acids
CN1181422A (zh) * 1996-10-31 1998-05-13 上海市肿瘤研究所 与生长因子受体结合的多肽所构建的基因转移载体
DE69833264T2 (de) * 1997-08-29 2006-09-28 Biogen Idec Ma Inc., Cambridge Verfahren und zusammensetzungen für die krebstherapie unter verwendung von interferon-beta codierenden genen
WO2000027198A1 (en) * 1998-11-09 2000-05-18 Abraham Nader G Retroviral vectors encoding interferon alpha and uses thereof
US6544780B1 (en) 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes

Also Published As

Publication number Publication date
AU2002303503B2 (en) 2007-09-20
MXPA03009763A (es) 2004-07-30
CA2445266A1 (en) 2002-11-07
CN100422322C (zh) 2008-10-01
WO2002087336A1 (en) 2002-11-07
CN1533242A (zh) 2004-09-29
AR040623A1 (es) 2005-04-13
EP1389043B1 (en) 2009-07-29
EP1389043A4 (en) 2004-09-08
US8058248B2 (en) 2011-11-15
ATE437656T1 (de) 2009-08-15
EP1389043A1 (en) 2004-02-18
JP2004530677A (ja) 2004-10-07
NZ529305A (en) 2005-08-26
DE60233127D1 (pt) 2009-09-10
US20030171314A1 (en) 2003-09-11

Similar Documents

Publication Publication Date Title
NO20026044D0 (no) Behandling av human papillomavirus
BR0209251A (pt) Vacina contra vìrus da febre aftosa
ATE233101T1 (de) Polynukleotide vakzine gegen den papilloma virus
EA200600582A1 (ru) Способы и композиции для лечения вирусного гепатита с
BR0308444A (pt) Composição de vacina, método de produção de vacina, uso de uma mistura de vlps de hpv 16, hpv 18, hvp 31 e hpv 45, método de prevenção da infecção por hpv ou tratamento de doença relacionada com a infecção por hpv
EA200201263A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
ATE500808T1 (de) Onkolytische virustherapie
BR9607146A (pt) Processo para proteger um animal de uma infecção viral e uma mulher de uma infecção transmitida através de relações sexuais vaginais para evitar o espalhamento de um patógeno viral de um indivuduo infectado a outros com bactérias transformadas para manipular a flora bacteriana mucosa de um hospedeiro e para inativar particulas vírais infecciosas em suprimentos de água suspeita e composição de matéria
DE60142683D1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen
DE69534992D1 (de) Mutierendes enterotoxin als nichttoxisches orales adjuvans
BR9106374A (pt) Vacina oral e processo de extrair uma imunoresponsta em um mamifero
MX9101810A (es) Vacuna contra virus de anemia de polio y diagnostico
EA200701633A1 (ru) Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1
WO2001060849A3 (en) Cold-adapted equine influenza viruses
DE602005008264D1 (de) Subtypabgestimmte inaktivierte vollvirusvakzine zur behandlung von patienten mit hiv-infektion
BR9811319A (pt) Método para proteger um animal contra umadoença crÈnica
PT1187631E (pt) Prevencao de diabetes de tipo 1 e de outras doencas provocadas por enterovirus nao-polio
TW200509964A (en) VP1 of foot-and-mouth disease virus
WO2001074386A3 (en) Cold-adapted equine influenza viruses
TW200503755A (en) Avian vaccine composition for the protection of poultry against disease and infection caused by e. coli and salmonella
DZ1550A1 (fr) Vaccin depourvu de cellules contre le virus de la maladie marek.
Pal Dengue fever: An emerging and re-emerging viral disease of major public health importance
ES2146574T3 (es) Secuencias de nucleotidos y polipeptidos, en particular del virus del colera del cerdo.
HUP9700975A2 (hu) Élő, legyengített, Pasteurellaceae családba tartozó, RTX-termelő baktériumok
DE69925312D1 (de) Bupropion zur behandlung von viralen erkrankungen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A(S) 9A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2103 DE 26/04/2011.